Short answer. The notice says compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed [1]. An enforcement policy does not fill that gap. As of Oct 29, 2026.

What the document is about

The policy is about who may compound, from what ingredient, by which route, with what paperwork [2]. HHS says it wants a more controlled alternative to research-use-only supply [2]. Control is not the same sentence as "this treats your injury," "this lengthens your life," or "this changes your weight."

Where HHS mentions human exposure, attribute it. For semax, HHS describes an intranasal record without reported adverse outcomes in the material CDER compiled [2]. For MOTS-c, HHS cites a trial of an analogue, not of every compounded product [2]. For epitalon, HHS says limited exposure reported no side effects and that regimens it looked at were intermittent [2]. None of those paragraphs is a labeled indication. None of them is a dose.

FDA's own briefing documents from July still sit on the evidence pages. Staff recommended against the bulks list. The policy prints that recommendation and proceeds with discretion anyway [2]. Hold both facts. Do not let the second delete the first.

What to do with a big claim

If a post says "HHS just proved BPC-157," ask for the page. The notice does not contain that proof [1]. The evidence pages remain the place for what the studies do and do not show: BPC-157, TB-500, KPV, MOTS-c, epitalon, semax.

Sommar Club does not prescribe or sell these six.

FAQ

Can I say the peptides are "allowed, so they work"? You can say HHS described enforcement discretion under conditions. You cannot get effectiveness from that sentence [1][2].

Did the policy set a dose that implies a benefit? No dose is printed in the discretion lines we used for these pages [2].

Sources

1. HHS notice, FR Doc. 2026-22192, filed Oct 28, 2026. https://public-inspection.federalregister.gov/2026-22192.pdf

2. HHS policy, Appendix B justifications. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf

Education only. Not medical or legal advice. As of Oct 29, 2026.